Singapore: Guizhou Taibang Biological Products, subsidiary of China Biologic Product, has collaborated  with Xinjiang Deyuan Bioengineering to source raw plasma.

The agreement allows Guizhou Taibang to source no less than 500 tonnes of source plasma from Xinjiang Deyuan over the next three years. The raw plasma will be shipped in batches to Guizhou Taibang for the production of human albumin and IVIG products. The company expects that the products made from the sourced raw plasma will begin to reach the market in second half of 2016.

As part of the agreement, Guizhou Taibang agreed to lend to Xinjiang Deyuan an interest-bearing loan with a principal amount of $47 million (RMB300 million)

Mr David (Xiaoying) Gao, chairman and chief executive officer, China Biologic, commented, "We are pleased to announce our strategic collaboration agreement with Xinjiang Deyuan. We have substantially processed the initial 143 tonnes of source plasma and plasma pastes outsourced from Xinjiang Deyuan in our first cooperation agreement, in April 2015. Through the initial agreement, we laid a solid foundation for our further collaboration, gained trust from both our business partners and regulators, and demonstrated our strong operational capabilities, including quality control and production management."